MAPK3 and colorectal carcinoma: Although we discovered that the combination of ERK1/2 and CDK4/6 inhibitors had a profound effect on CRC treatment in vitro and in vivo, the effect of palbociclib or SCH772984 alone in vivo is yet to be investigated.